Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07022249

Evaluation of a Novel Intrasaccular Embolization Device for the Treatment of Intracranial Aneurysms

The study is a prospective, multicenter single-arm cohort. The purpose of this study is to evaluate efficacy and safety of a novel intrasaccular embolization device for the treatment of intracranial aneurysms.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient must be 18-75 years of age at the time of screening.
  • Patient must have a single ruptured or unruptured IA requiring treatment.
  • Patient was able to comply with all aspects of the screening, evaluation, treatment, and the post-procedure follow-up schedule, signed and dated an written informed consent prior to initiation of any study procedures.

Exclusion criteria

  • Patient had an IA with characteristics unsuitable for endovascular treatment.
  • Patient had vessel characteristics, tortuosity or morphology which precluded safe access and support during treatment with study device.
  • Patient had vascular disease or other vascular anomaly that precluded the necessary access to the aneurysm for use of the study device.
  • Patient had vasculitis, an intracranial tumor (except benign tumors that do not require treatment) or any other intracranial vascular malformations on presentation.
  • Patient was taking anticoagulants or had a known blood dyscrasia, coagulopathy, or hemoglobinopathy.
  • Patient was pregnant.

Treatment and study plan

Intrasaccular Embolization Device

Device

This is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.The intended therapeutic effect of this device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant.

Primary outcomes

  1. The Primary Safety Endpoint Included Any Death or Major Stroke in the First 30 Days and Neurologic Death or Ipsilateral Major Stroke Between Day 31 and Day 365.

    Time frame: 12 months

  2. Percentage of Subjects With Complete Aneurysm Occlusion Without Retreatment, Recurrent Subarachnoid Hemorrhage, Without Significant Parent Artery Stenosis (>50% Stenosis) at One Year After Treatment.

    Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Xiaoyan Yang

CONTACT

[email protected]

18577072001

Sponsors and collaborators

Lead sponsor

Ton-Bridge Medical Tech. Co., Ltd

Industry

Registry information

Official study title

Efficacy and Safety of a Novel Intrasaccular Embolization Device for the Treatment of Intracranial Aneurysms : a Prospective, Multicenter, Single-arm Trial

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jun 15, 2025
Registry last updated
Jun 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.